Table 2.
Intragroup analysis of different outcome measures between baseline and week 12.
| Variables | Rivastigmine baseline | Rivastigmine week 12 | t | p | CI | Placebo baseline | Placebo week 12 | t | p | CI |
|---|---|---|---|---|---|---|---|---|---|---|
| PANSS-positive symptoms | 16.2 ± 4.4 | 14.2 ± 4.4 | 1.36 | 0.18 | −0.98, 4.98 | 15.4 ± 4 | 13.8 ± 4.1 | 1.18 | 0.24 | −1.14, 4.34 |
| PANSS-negative symptoms | 19.6 ± 9.2 | 17.2 ± 9.6 | 0.76 | 0.44 | −3.97, 8.77 | 21.1 ± 9.1 | 19 ± 9 | 0.69 | 0.49 | −4.03, 8.23 |
| PANSS-general psychopathology | 36.1 ± 7.6 | 34.6 ± 6.9 | 0.62 | 0.53 | −3.42, 6.42 | 38.5 ± 8.2 | 37.5 ± 7.8 | 0.37 | 0.71 | −4.42, 6.42 |
| MMSE | 24.1 ± 2.9 | 27.1 ± 2.1 | −3.55 | 0.001 | −4.72, –1.28 | 23 ± 3.2 | 23.1 ± 3.2 | −0.09 | 0.92 | −2.27, 2.07 |
| CGI-I | 3.03 ± 0.14 | 2.66 ± 0.78 | 1.98 | 0.05 | −0.01, 0.75 | 3.06 ± 0.26 | 3.01 ± 0.38 | 0.46 | 0.64 | −0.17, 0.27 |
| ESRS | 8.7 ± 2.6 | 10 ± 3.4 | −1.28 | 0.20 | −3.35, 0.75 | 9 ± 2.6 | 10 ± 2.5 | −1.17 | 0.24 | −2.73, 0.73 |
CGI-I, Clinical Global Impressions-Improvement; ESRS, Extrapyramidal Symptom Rating Scale; MMSE, Mini Mental State Examination; PANSS, Positive and Negative Symptom Scale.